Loading...
•
Jul 31, 2022
Avid Bioservices Q1 2023 Earnings Report
Established a new high in revenue, driven by new business and exceptional manufacturing performance.
Key Takeaways
Avid Bioservices reported a strong first quarter for fiscal year 2023, with record revenue of $36.7 million and $41 million in new project orders, leading to a record backlog of $157 million. The company's mammalian and cell and gene therapy businesses are expanding as planned.
Recorded First Quarter Revenue of $36.7 Million.
Signed $41 Million in Net New Business Orders.
Ended the Quarter with a Record High Backlog of $157 Million.
Facilities and Capabilities Expansions in Mammalian and Cell and Gene Therapy Businesses Continue on Schedule.
Forward Guidance
Fiscal 2023 will be transformational for Avid, and the company looks forward to reporting many exciting milestones ahead.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...